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A  vaccine  against  malaria  is urgently  needed  for control  and  eventual  eradication.  Different  approaches
are  pursued  to induce  either  sterile  immunity  directed  against  pre-erythrocytic  parasites  or  to mimic
naturally  acquired  immunity  by  controlling  blood-stage  parasite  densities  and  disease  severity.  Pre-
erythrocytic  and  blood-stage  malaria  vaccines  are  often  seen  as  opposing  tactics,  but it is likely that  they
have to be  combined  into  a  multi-stage  malaria  vaccine  to  be optimally  safe  and effective.
Since  many  antigenic  targets  are  shared  between  liver-  and  blood-stage  parasites,  malaria  vaccines
have  the  potential  to elicit  cross-stage  protection  with  immune  mechanisms  against  both  stages  com-
plementing  and  enhancing  each  other.  Here  we  discuss  evidence  from  pre-erythrocytic  and  blood-stage
subunit  and  whole  parasite  vaccination  approaches  that  show  that  protection  against  malaria  is  not  nec-
essarily  stage-speciﬁc.  Parasites  arresting  at late  liver-stages  especially,  can  induce  powerful  blood-stage
immunity,  and  similarly  exposure  to  blood-stage  parasites  can  afford  pre-erythrocytic  immunity.The incorporation  of  a blood-stage  component  into  a multi-stage  malaria  vaccine  would  hence  not  only
combat  breakthrough  infections  in  the blood  should  the  pre-erythrocytic  component  fail  to induce  sterile
protection,  but  would  also  actively  enhance  the pre-erythrocytic  potency  of  this  vaccine.  We  therefore
advocate  that  future  studies  should  concentrate  on  the  identiﬁcation  of  cross-stage  protective  malaria
antigens,  which  can  empower  multi-stage  malaria  vaccine  development.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Background
Malaria remains a major global health scourge and there is
 general consensus that elimination and eradication efforts will
ot be successful without an effective malaria vaccine. In malaria
ndemic areas, immunity against severe disease caused by blood-
tage parasites can be acquired after only one or two infections,
hile infections with high parasite densities still occur [1]. Vac-
ines targeting blood-stage parasites should equally induce control
f (severe) disease but ultimately also clearance of blood-stage
arasites. This is essential as gametocytes form during blood-stage
nfection and transmission to mosquitoes can otherwise continue.
Abbreviations: AMA-1, apical membrane antigen 1; CPS, chemoprophylaxis and
porozoites; iv, intravenous; MSP-1, merozoite surface protein 1.
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There is only very limited evidence for protection against
pre-erythrocytic malaria parasites (sporozoites and liver-stage
parasites) in naturally exposed populations [2–4]. Pre-erythrocytic
vaccines aim to outperform naturally acquired immunity by tar-
geting the clinically silent stages of infection thus precluding any
parasites reaching the blood stream. This would abolish any symp-
toms of malaria and additionally block transmission. The risk
of such an approach is however that breakthrough blood-stage
infections can cause severe complications, if the pre-erythrocytic
vaccine is only partially effective. Therefore a blood-stage compo-
nent should be included to minimize this risk [5,6]. This is especially
important since it was suggested that declining transmission inten-
sity and thus reduced boosting of clinically protective blood-stage
immunity could in fact increase overall malaria morbidity [7].
The desired scenario would therefore be to develop a multi-stage
malaria vaccine that minimizes both transmission and disease [8].
2. Hypothesis: Shared antigenic targets between liver and
blood-stage parasites can induce cross-stage immunityGiven that there are shared antigens between the different
life cycle stages of the malaria parasite [9], it is possible that
functional immunity to pre-erythrocytic and blood-stage parasites
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ould enhance each other, offering an intriguing possibility for
evelopment of a multi-stage malaria vaccine. Evidence for cross-
tage immunity comes from several studies [10–13]. For instance,
pical membrane antigen (AMA)-1 and the unprocessed form of
erozoite surface protein (MSP)-1 are highly abundant in blood-
tage parasites with roles in erythrocyte invasion [14,15]; however
hese antigens are also expressed by sporozoites and liver-stage
arasites [16,17]. In human volunteers immunized with AMA-1
he number of blood-stage parasites during the ﬁrst blood-stage
ycle after mosquito bite challenge infection was about 7-times
ower compared to non-immunized controls, suggesting that pre-
rythrocytic immune responses may  have eliminated sporozoites
r infected hepatocytes [13]. Indeed an 80% reduction of liver-stage
arasite burden following sporozoite challenge was shown in mice
mmunized with AMA-1 [10]. After vaccination of humans with
MA-1 and MSP-1, time to diagnosis, which was  delayed in the
accinees, signiﬁcantly correlated with liver-to-blood parasite lev-
ls but not blood-stage multiplication rates. This suggests again that
his vaccine may  induce pre-erythrocytic rather than the originally
ntended blood-stage immunity [12]. These examples indicate that
nly one or two malarial antigens, which are expressed in both
iver- and blood-stage parasites, can induce cross-stage protective
mmunity. Whole parasite vaccines that allow exposure to many
arasite antigens should therefore provide greater potential for
ross-stage immunity, which would enhance protection induced by
re-erythrocytic and blood-stage parasites. We  therefore discuss
vidence for cross-stage immunity from different whole parasite
accination approaches, which offers the opportunity to identify
s yet unknown cross-protective antigens for multi-stage malaria
accine development.
. Evidence for cross-stage immunity from
re-erythrocytic whole parasite vaccination approaches
The proteome of liver-stage parasites becomes increasingly
imilar to blood-stage parasites as liver development proceeds
9]. Late liver-stage schizonts contain up to 40,000 merozoites
ach [18], which can upon release invade erythrocytes. Further-
ore the amount of parasite antigen increases as the parasite
atures in hepatocytes. Killed sporozoites that fail to invade
epatocytes are incapable of inducing protection [19,20], suggest-
ng that liver-stage development is indispensable for induction
f protective immunity. Irradiation of sporozoites, which arrests
heir development early during the liver-stage [21,22], induces
mmunity to pre-erythrocytic stages only [19,23]. A very limited
umber of studies have, however, investigated whether there
re signiﬁcant immune responses, or any level of protection
gainst blood-stage parasites. One report from Krzych et al.
24] suggests a more in-depth study of cross-stage immune
esponses induced by irradiation attenuated sporozoites might
e valuable, as T cells from human volunteers immunized with
rradiated sporozoites responded to both pre-erythrocytic and
lood-stage antigens, including MSP-1. This response was greater
n immunized volunteers, who were protected from challenge
nfection, than in unprotected volunteers and comparable to
alaria-experienced individuals [24]. Therefore, immunization of
umans with irradiated sporozoites leads to the induction of
mmune responses recognizing blood-stage antigens. CD8T cells,
hich were shown to be essential for pre-erythrocytic protection
ollowing irradiated sporozoites immunization [25], proliferate
ore strongly in mice if in addition to Plasmodium bergheirradiated sporozoites they were exposed to blood-stage para-
ites [26]. This suggests that blood-stage infection can enhance
re-erythrocytic vaccine efﬁcacy. Furthermore in a P. berghei infec-
ion model in mice, multiple booster immunizations with high 33 (2015) 7513–7517
numbers of irradiated sporozoites resulted in delayed patency and
reduced peak blood-stage parasitemia after sporozoite challenge
(Nganou-Makamdop K, personal communication), suggesting that
cross-stage protective responses targeting blood-stage parasites
may have developed. It has however also been observed that a
fulminant blood-stage infection can suppress protective immune
responses elicited by irradiated sporozoites against liver-stage
antigens [27]. Possible negative interferences between immunity
directed against liver and blood-stage parasites can therefore not be
excluded.
Targeted deletion of parasite genes important for liver-stage
development is an alternative strategy to arrest parasite devel-
opment in hepatocytes. Similar to irradiated and chemically
attenuated [28] sporozoites, immunization with knock-out para-
sites that arrest during the early liver-stage (e.g. uis 3 [29], uis 4 [30],
p36p [31], sap-1 [32], p52/p36 [33,34]) results in pre-erythrocytic
immunity. Late arrest during liver-stage development [35], how-
ever, appears to increase the chance of cross-stage immunity:
Immunization with P. yoelii fabb/f knockout sporozoites can control
and clear blood-stage parasitemia following challenge with blood-
stage parasites, possibly by inducing an effective T cell response
[36]. This is the ﬁrst direct evidence that immunization with an
attenuated parasite, which does not develop beyond liver-stage,
can elicit blood-stage immunity.
Cross-stage immunity therefore appears to be more efﬁcient if
liver-stage parasites arrest late in development as their antigenic
proﬁle becomes similar to blood-stage parasites [9] and the amount
of antigen increases (Fig. 1). Hence antigens expressed in late liver-
stage parasites are, under certain conditions, capable of mediating
not only pre-erythrocytic protection, but also reduce the risk of
blood-stage breakthrough infection by inducing effective blood-
stage immunity.
4. Evidence for cross-stage immunity from whole
blood-stage parasite vaccination approaches
Plasmodium replicates massively in the liver such that one
infected hepatocyte can release up to up to 40,000 blood-stage
parasites [37]. Also due to their subsequent exponential multi-
plication, blood-stage parasites are hence much more numerous
than pre-erythrocytic parasites, which increases their potential
to present protective antigens successfully. The possibility that
immune responses against these antigens might not be only speciﬁc
for blood-stage parasites, but could also target pre-erythrocytic
stages has however hardly been investigated (Fig. 1).
Disruption of the purine nucleoside phoshphorylase gene (pnp)
[38] or nucleoside transporter 1 (nt1) gene [39] in P. yoelii gives
rise to severely attenuated blood-stage infections, and mice that
had undergone an infection with these knockout parasites did not
develop detectable patent blood-stage parasitemia after infectious
mosquito bite or sporozoite challenge [38,39]. This could repre-
sent effective blood-stage or pre-erythrocytic immunity, since a
reduction in liver parasite burden, which is the only direct evidence
for pre-erythrocytic protection, was not shown. Direct evidence for
pre-erythrocytic protection elicited by blood-stage parasites comes
from mice that received a prophylactic treatment with chloroquine
and were simultaneously infected with P. yoelii blood-stage para-
sites. Liver parasite burden is signiﬁcantly reduced in these mice
following sporozoite challenge [40].
It is presumed that the main purpose of blood-stage compo-
nents in a multi-stage vaccine is to protect against breakthrough
blood-stage infection [41], if the pre-erythrocytic components are
only partially effective. However, since whole parasite blood-stage
immunizations have the potential to also induce cross-stage pro-
tective responses enhancing immunity against pre-erythrocytic
W.  Nahrendorf et al. / Vaccine 33 (2015) 7513–7517 7515
Fig. 1. Shared antigens between liver and blood-stage malaria parasites can induce cross-stage immunity.
Malaria infection is initiated by an infectious mosquito bite, which inoculates a few sporozoites into the skin. Sporozoites then migrate to the liver and invade hepatocytes.
During  pre-erythrocytic development (which last 7 days for Plasmodium falciparum) parasite load slowly increases as Plasmodium matures in the liver. In addition, the
antigenic repertoire becomes increasingly similar to blood-stage parasites [9] and cross-stage antigens are expressed. Late liver schizonts contain up to 40,000 merozoites
[18], which are released into the blood-stream as merosomes surrounded by a host cell membrane [53]. When each merozoite invades an individual red blood cell parasite
load  rises rapidly. Blood-stage parasites mature from rings to trophozoites and schizonts and parasite load increases exponentially with each new replication cycle (P.
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arasites could induce cross-stage immunity. Characterization of these antigens wo
tages, blood-stage antigens might be even more valuable for multi-
tage malaria vaccine development.
. Is cross-stage immunity responsible for the
nprecedented efﬁciency of chemoprophylaxis with
porozoites immunization?
The induction of cross-stage immunity should be facilitated by
xposure to both pre-erythrocytic and blood-stage parasites during
mmunization. Chemoprophylaxis with sporozoites (CPS) immu-
ization, which uses infectious wild-type sporozoites combined
ith prophylactic antimalarial drug treatment (often chloroquine),
llows the immune system to experience all vertebrate Plasmo-
ium life cycle stages including sporozoites, infected hepatocytes
nd blood-stage parasites. CPS immunization was ﬁrst described
n rodents [42,43] and was later shown to induce long lasting
terile protection against homologous mosquito-bite challenge in
uman volunteers [44–46]. In humans CPS immunization is about
0 times more efﬁcient than immunization with irradiated sporo-
oites [23,47]. We  therefore hypothesize that the completion of
iver-stage development and the exposure to blood-stage parasites
40] during CPS immunization may  enhance the protective efﬁcacy
y inducing protective cross-stage responses. CPS immunization
sing primaquine – a drug that primarily targets liver-stage para-
ites – substantially reduces the number of sterilely protected
ice thereby strengthening this hypothesis [20]. In further sup-
ort of this, mice that have experienced a self-cured infection
ith P. chabaudi blood-stage parasites derived from a donor mouse
nfected by mosquito bite have a substantially reduced liver-
arasite burden following mosquito bite challenge [48]. Cross-stage
mmunity elicited by blood-stage parasites may  hence contribute tontigens infected erythrocytes also express cross-stage antigens, which are shared
ization approaches that shared antigens between pre-erythrocytic and blood-stage
reatly facilitate multi-stage malaria vaccine development.
the unprecedented efﬁciency of CPS immunization to induce sterile
pre-erythrocytic protection in human volunteers [44–46]. Impor-
tantly exposure to blood-stage parasites during CPS immunization
may  signiﬁcantly contribute to the observed pre-erythrocytic pro-
tection against mosquito bite challenge, but does not appear to
protect against direct blood-challenge within the ﬁrst four cycles
of blood-stage replication [45]. In human volunteers CPS immu-
nization induces both T cell and antibody responses, which may
be implicated in protection [46,49–51]. Protective target antigens
and the exact mechanism of protective immunity are however still
unclear.
6. Conclusion: Importance of studying cross-stage
immunity for malaria vaccine development
Cross-stage immunity would be a powerful means to improve
protective efﬁcacy of malaria vaccines, however data to support
this hypothesis are sparse. During liver-stage development both
the amount of antigen and the antigenic similarity to blood-stage
parasites increases (Fig. 1). Thus as Plasmodium matures in the liver,
it is potentially capable of inducing immunity not only against pre-
erythrocytic but also against blood-stage parasites [36]. Equally,
exposure to attenuated blood-stage parasites could protect against
sporozoite challenge [40].
Future studies should therefore investigate the potential of
cross-stage immunity directly. In our opinion whole parasite
immunization approaches are particularly useful to answer the
question whether cross-stage immunity contributes to protec-
tion and to identify protective cross-stage antigens for subunit
malaria vaccine development. If however a whole parasite immu-
nization strategy were proven to be safe, effective and practical
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rst, there would be no reason not to implement it. Pre-erythrocytic
accines should evaluate blood-stage protection after direct injec-
ion of blood-stage parasites, while blood-stage vaccines should
emonstrate whether liver-parasite burden is reduced follow-
ng sporozoite challenge. If cross-stage immune responses can
e elicited, target antigens and crucial immunological mecha-
isms mediating it should be characterized using proteome-wide
creening approaches (immunomics) of antibody and T cell reac-
ivity comparing protected and unprotected individuals [51,52].
electing antigens capable of inducing cross-stage protection could
reatly facilitate the development of a multi-stage malaria vaccine
y increasing potency.
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